A startup launches with plans to open up a gene and cell therapy bottleneck

Date Published01/31/2023
Author NameGwendolyn Wu
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Vector BioMed
Parent companyVector BioMed
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2023
Capital investment ($):15
City reshored to:Gaithersburg
State(s) reshored to:MD
If relevant, work nearshored to:-
Product(s) reshoredpharma, lentiviral vectors
What domestic positive factors made reshoring more attractive?Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market
Find Reshoring Articles